Literature DB >> 29374075

Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity.

Blake F Frey1, Jiansheng Jiang2, Yongjun Sui3, Lisa F Boyd2, Bin Yu4, Gwen Tatsuno4, Rolf Billeskov1, Shahram Solaymani-Mohammadi1, Phillip W Berman4, David H Margulies2, Jay A Berzofsky1.   

Abstract

Unlike cytosolic processing and presentation of viral Ags by virus-infected cells, Ags first expressed in infected nonprofessional APCs, such as CD4+ T cells in the case of HIV, are taken up by dendritic cells and cross-presented. This generally requires entry through the endocytic pathway, where endosomal proteases have first access for processing. Thus, understanding virus escape during cross-presentation requires an understanding of resistance to endosomal proteases, such as cathepsin S (CatS). We have modified HIV-1MN gp120 by mutating a key CatS cleavage site (Thr322Thr323) in the V3 loop of the immunodominant epitope IGPGRAFYTT to IGPGRAFYVV to prevent digestion. We found this mutation to facilitate cross-presentation and provide evidence from MHC binding and X-ray crystallographic structural studies that this results from preservation of the epitope rather than an increased epitope affinity for the MHC class I molecule. In contrast, when the protein is expressed by a vaccinia virus in the cytosol, the wild-type protein is immunogenic without this mutation. These proof-of-concept results show that a virus like HIV, infecting predominantly nonprofessional presenting cells, can escape T cell recognition by incorporating a CatS cleavage site that leads to destruction of an immunodominant epitope when the Ag undergoes endosomal cross-presentation.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29374075      PMCID: PMC5890335          DOI: 10.4049/jimmunol.1701523

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo.

Authors:  Lianjun Shen; Luis J Sigal; Marianne Boes; Kenneth L Rock
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

2.  Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.

Authors:  Stefan Tenzer; Edmund Wee; Anne Burgevin; Guillaume Stewart-Jones; Lone Friis; Kasper Lamberth; Chih-hao Chang; Mikkel Harndahl; Mirjana Weimershaus; Jan Gerstoft; Nadja Akkad; Paul Klenerman; Lars Fugger; E Yvonne Jones; Andrew J McMichael; Søren Buus; Hansjörg Schild; Peter van Endert; Astrid K N Iversen
Journal:  Nat Immunol       Date:  2009-05-03       Impact factor: 25.606

3.  A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160.

Authors:  H Takahashi; S Merli; S D Putney; R Houghten; B Moss; R N Germain; J A Berzofsky
Journal:  Science       Date:  1989-10-06       Impact factor: 47.728

4.  Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy.

Authors:  Rolf Billeskov; Yichuan Wang; Shahram Solaymani-Mohammadi; Blake Frey; Shweta Kulkarni; Peter Andersen; Else Marie Agger; Yongjun Sui; Jay A Berzofsky
Journal:  J Immunol       Date:  2017-03-27       Impact factor: 5.422

5.  Vaccine-induced myeloid cell population dampens protective immunity to SIV.

Authors:  Yongjun Sui; Alison Hogg; Yichuan Wang; Blake Frey; Huifeng Yu; Zheng Xia; David Venzon; Katherine McKinnon; Jeremy Smedley; Mercy Gathuka; Dennis Klinman; Brandon F Keele; Sol Langermann; Linda Liu; Genoveffa Franchini; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

Review 6.  Immunological strategies to target HIV persistence.

Authors:  Glòria Martrus; Marcus Altfeld
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

7.  Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.

Authors:  I M Belyakov; L S Wyatt; J D Ahlers; P Earl; C D Pendleton; B L Kelsall; W Strober; B Moss; J A Berzofsky
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

9.  Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120.

Authors:  H Li; K Natarajan; E L Malchiodi; D H Margulies; R A Mariuzza
Journal:  J Mol Biol       Date:  1998       Impact factor: 5.469

10.  Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity.

Authors:  Mitsuo Honda; Rui Wang; Wing-Pui Kong; Masaru Kanekiyo; Wataru Akahata; Ling Xu; Kazuhiro Matsuo; Kannan Natarajan; Howard Robinson; Tedi E Asher; David A Price; Daniel C Douek; David H Margulies; Gary J Nabel
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

View more
  7 in total

1.  Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.

Authors:  Sophia W Li; Bin Yu; Gabriel Byrne; Meredith Wright; Sara O'Rourke; Kathryn Mesa; Phillip W Berman
Journal:  Biotechnol Bioeng       Date:  2019-06-10       Impact factor: 4.530

Review 2.  Strategies for developing and optimizing cancer vaccines.

Authors:  Hoyoung M Maeng; Jay A Berzofsky
Journal:  F1000Res       Date:  2019-05-13

3.  Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.

Authors:  Hakimeh Ebrahimi-Nik; Justine Michaux; William L Corwin; Grant Lj Keller; Tatiana Shcheglova; HuiSong Pak; George Coukos; Brian M Baker; Ion I Mandoiu; Michal Bassani-Sternberg; Pramod K Srivastava
Journal:  JCI Insight       Date:  2019-06-20

4.  Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope.

Authors:  Marmar Moussa; Ryan P Englander; Hakimeh Ebrahimi-Nik; Summit Singhaviranon; Justine Michaux; HuiSong Pak; Hiroko Miyadera; William L Corwin; Grant L J Keller; Adam T Hagymasi; Tatiana V Shcheglova; George Coukos; Brian M Baker; Ion I Mandoiu; Michal Bassani-Sternberg; Pramod K Srivastava
Journal:  Nat Commun       Date:  2021-11-05       Impact factor: 14.919

5.  Comparison of HIV-1 Vif and Vpu accessory proteins for delivery of polyepitope constructs harboring Nef, Gp160 and P24 using various cell penetrating peptides.

Authors:  Kimia Kardani; Atieh Hashemi; Azam Bolhassani
Journal:  PLoS One       Date:  2019-10-31       Impact factor: 3.240

6.  Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines.

Authors:  Nicola Borthwick; Sandra Silva-Arrieta; Anuska Llano; Masafumi Takiguchi; Christian Brander; Tomáš Hanke
Journal:  Vaccines (Basel)       Date:  2020-01-16

Review 7.  New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection.

Authors:  Marisierra Espinar-Buitrago; Ma Angeles Muñoz-Fernández
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.